{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-000084","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.480240+00:00","generated_at":"2026-05-28T18:59:16.805533+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neumora's Phase 3 KOASTAL-1 study of navacaprant fails primary endpoint in MDD","bullets":["Primary endpoint MADRS total score change at Week 6: -12.5 for both navacaprant and placebo (p=0.993); no statistical improvement.","Key secondary endpoint SHAPS also missed: -5.8 vs -5.5 (p=0.648).","Pre-specified subgroup analysis showed efficacy signal in females: MADRS LSMD -2.7 (p=0.072); SHAPS LSMD -2.3 (p=0.015).","Navacaprant generally well-tolerated; no serious adverse events; discontinuation 2.1% vs 3.1% for placebo.","Cash balance $342M provides runway into mid-2026; J.P. Morgan Healthcare Conference update planned Jan 14."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-000084","json":"https://secwatch.observer/filing/0001193125-25-000084.json","markdown":"https://secwatch.observer/filing/0001193125-25-000084.md","text":"https://secwatch.observer/filing/0001193125-25-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525000084/0001193125-25-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525000084/d859264d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T18:59:16.805533+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}